The US Food and Drug Administration (FDA) has approved a once-daily treatment with netarsudil and latanoprost ophthalmic solution (Rocklatan, Aerie Pharmaceuticals) to decrease elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, the company has announced.
Rocklatan is the first and only once-daily, fixed-dose combination of a prostaglandin analog (latanoprost) and the first-in-class rho-associated protein kinase (ROCK) inhibitor (netarsudil), according to the company.
Netarsudil is the active ingredient in Rhopressa (Aerie Pharmaceuticals), which was approved by the FDA in February 2018 as a once-daily treatment for open-angle glaucoma or ocular hypertension. Netarsudil targets the trabecular outflow pathway, countering the stiffening and contraction of the meshwork that elevates ocular pressure.
